← Back to Search

Monoclonal Antibodies

Erenumab for Hemicrania Continua

Phase 2
Waitlist Available
Led By Rashmi Halker Singh, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks post erenumab treatment
Awards & highlights

Study Summary

This trial is testing a new drug, erenumab, to see if it can effectively treat hemicrania continua, as well as if it is safe and tolerable for patients.

Eligible Conditions
  • Hemicrania Continua

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks post erenumab treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks post erenumab treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Headache Days
Secondary outcome measures
Headache Freedom
Migraine Days
Remission Rate

Side effects data

From 2023 Phase 4 trial • 701 Patients • NCT04084314
35%
COVID-19
19%
Nasopharyngitis
15%
Constipation
9%
Fatigue
7%
Hypertension
6%
Migraine
6%
Back pain
6%
Headache
6%
Depression
6%
Immunisation reaction
5%
Nausea
5%
Arthralgia
4%
Vertigo
4%
Alopecia
4%
Pain in extremity
3%
Dizziness
3%
Tonsillitis
3%
Cystitis
3%
Oropharyngeal pain
3%
Urinary tract infection
3%
Pyrexia
3%
Pruritus
3%
Cough
3%
Chills
2%
Abdominal pain upper
2%
Muscle spasms
2%
Osteoarthritis
2%
Post vaccination fever
2%
Procedural pain
2%
Diarrhoea
1%
Appendicitis
1%
Intervertebral disc protrusion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Erenumab

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment with ErenumabExperimental Treatment1 Intervention
Subjects diagnosed with hemicrania continua will receive single dose of Erenumab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Erenumab
FDA approved

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,245 Previous Clinical Trials
3,783,439 Total Patients Enrolled
Rashmi Halker Singh, MDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
19 Total Patients Enrolled
~1 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top